IRF8 defines the epigenetic landscape in postnatal microglia, thereby directing their transcriptome programs

In “Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model” (page not available), the paper reports that amyloid load was smaller in year-old 5xFAD/IRF8KO brains than in controls. It says the number of ThioS-positive aggregates was similar, but that is not the same as unchanged overall Aβ accumulation. The cited passage does not report the claimed result for four-month-old female mice. (LLM, conf=0.88)

Checked by a reasoning model — may be wrong.

The ‘Irf8 deletion ameliorates AD pathology’ section reports smaller plaques in year-old 5xFAD/IRF8KO mice, consistent with the size claim. But it says the number of ThioS-positive aggregates was similar to that in 5xFAD/WT mice, not increased. Figure 7’s caption identifies these as measurements from year-old brains; the Methods state that female mice were used unless specified. (LLM, conf=0.90)

Checked by a reasoning model — may be wrong.

The Introduction (page unavailable) describes PU.1 and IRF8 in microglial development, while the section on IRF8-directed transcription cascades reports that IRF8 activates SALL1 and BATF3 to regulate microglial genes. Our copy does not establish a PU.1-low, CD28-positive microglial state or connect it to MEF2C, so the proposed specific outcome and the full list of factors are not supported. (LLM, conf=0.86)

The sections on stepwise IRF8 binding and microglia-specific enhancers report increasing IRF8 occupancy during postnatal development and its role in forming enhancers (pages unavailable). The paper also describes an IRF8–PU.1 composite motif and identifies SALL1 as a downstream factor, but it does not show stepwise binding to enhancers together with both SALL1 and PU.1. (LLM, conf=0.88)

The Introduction (page not available) says embryonic microglial progenitors expand in an IRF8-dependent manner, supporting a role for Irf8 in expansion. The paper does not establish that Irf8 is critical for microglial survival, or that Csf1 and Csf1r are critical for both survival and proliferation; searches for Csf1 and Csf1r found no such passage. (LLM, conf=0.81)

In “Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model” (page unavailable), the paper reports reduced colocalization of Aβ with IRF8KO microglia and suggests impaired Aβ recognition and perhaps internalization. It does not report a Methoxy-X04 in vivo phagocytosis assay or a significant decrease in probe-positive microglia in six-month-old male mice; searches for those terms found no such result. (LLM, conf=0.83)

In “Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model” (page unavailable), the paper reports smaller plaques and suggests that IRF8-deficient microglia may be defective in recognizing and internalizing Aβ. It reports a similar number of ThioS-positive aggregates between groups, however, and does not report the cited Methoxy-X04 in vivo phagocytosis assay in six-month-old male mice. The proposed impairment is therefore partly supported, but the assay and plaque-number details are not. (LLM, conf=0.85)

The transcription-cascade results state that IRF8 activates Sall1, and the genome-binding results report IRF8 binding near Cx3cr1; the RNA-seq results also report lower CX3CR1 on IRF8-knockout microglia. These passages support IRF8’s contribution to SALL1 and CX3CR1 expression, but the copy does not establish that PU.1 directly activates IRF8 or that IRF8 activates STING/TMEM173 (searched both terms). The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)

The AD-pathology results and Figure 7 caption report smaller cortical Aβ plaques in year-old 5xFAD/IRF8KO mice. But the Mice section distinguishes the constitutive IRF8KO mice used for that comparison from postnatal microglia-specific IRF8cKO mice. The results also say the number of ThioS-positive aggregates was similar between groups, not increased as the printed citing sentence states. (LLM, conf=0.90)

In “Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model” (Fig. 7C–D; page unavailable), plaque size was smaller in 5xFAD/IRF8KO brains, but the number of ThioS-positive aggregates was similar to controls—not increased. The Fig. 7 legend identifies the images as cortex from year-old mice, but labels this comparison IRF8KO rather than postnatal microglia-specific IRF8cKO. (LLM, conf=0.90)

In “Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model” (page unavailable), the paper reports reduced Aβ–microglia colocalization and suggests impaired Aβ recognition and perhaps internalization. It does not establish decreased phagocytic activity: internalization is presented as a possibility, not a measured outcome. The cortical histology shown is from year-old 5xFAD/IRF8KO mice, not six-month-old mice with postnatal microglia-specific deletion. (LLM, conf=0.88)

The ‘Irf8 deletion ameliorates AD pathology’ section reports less colocalization of Aβ with microglia in 5xFAD/IRF8KO brains, supporting reduced interaction. However, the cortical plaque analysis used year-old mice, not six-month-old mice, and compared IRF8KO rather than postnatal microglia-specific conditional deletion. The paper suggests impaired Aβ internalization but does not establish decreased phagocytic activity in that experiment. (LLM, conf=0.90)

The Introduction describes PU.1 interacting with IRF8, and the bulk RNA-seq section reports that IRF8 regulates downstream genes involved in microglial identity, lysosomal activity, and interferon signaling (page not provided). Our copy does not establish a role for BHLHE40/41 in this regulation or specifically show that these factors jointly control phagocytosis and cytokine production. (LLM, conf=0.88)

The Introduction and the section ‘Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model’ report altered microglial gene expression after Irf8 deletion alongside reduced amyloid burden in an Alzheimer’s mouse model; the figure description locates the plaque and neuronal analyses in the cortex. The paper does not establish that transcriptional remodeling ameliorates microglial activation or functional changes in both cortical and hippocampal regions. No page numbers are available in our copy. (LLM, conf=0.85)

The bulk RNA-seq results and Discussion describe IRF8-dependent microglial transcriptional programs, not activation by a HAF1 complex. Searches for HAF1 and the listed genes found no passage in our copy establishing the attributed claim; the paper’s broader findings about IRF8 do not verify it. (LLM, conf=0.72)

The bulk RNA-seq results report aberrant upregulation of interferon-related genes after IRF8 deletion, and the section on continuous IRF8 expression discusses Sall1 and Batf3. Neither passage addresses whether MEF2C suppresses excessive pro-inflammatory responses. Searches for MEF2C and its proposed anti-inflammatory role found no supporting passage in our copy. (LLM, conf=0.76)